Base resolution methylome profiling: considerations in platform selection, data preprocessing and analysis
- PMID: 26366945
- PMCID: PMC4790440
- DOI: 10.2217/epi.15.21
Base resolution methylome profiling: considerations in platform selection, data preprocessing and analysis
Abstract
Bisulfite treatment-based methylation microarray (mainly Illumina 450K Infinium array) and next-generation sequencing (reduced representation bisulfite sequencing, Agilent SureSelect Human Methyl-Seq, NimbleGen SeqCap Epi CpGiant or whole-genome bisulfite sequencing) are commonly used for base resolution DNA methylome research. Although multiple tools and methods have been developed and used for the data preprocessing and analysis, confusions remains for these platforms including how and whether the 450k array should be normalized; which platform should be used to better fit researchers' needs; and which statistical models would be more appropriate for differential methylation analysis. This review presents the commonly used platforms and compares the pros and cons of each in methylome profiling. We then discuss approaches to study design, data normalization, bias correction and model selection for differentially methylated individual CpGs and regions.
Keywords: DNA methylation; bisulfite sequencing; differential methylation; methylation 450K array; normalization; reduced representation bisulfite sequencing; study design.
Conflict of interest statement
Financial & competing interests disclosure This work is partially supported by Division of Biomedical Statistics and Informatics Meritorious Award (to Z Sun), Mayo Clinic Center for Individualized Medicine and National Cancer Institute (NCI R01CA118444 to S Slager). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.
Figures
References
-
- Azuara D, Rodriguez-Moranta F, de Oca J, et al. Novel methylation panel for the early detection of colorectal tumors in stool DNA. Clin. Colorectal Cancer. 2010;9(3):168–176. - PubMed
-
- Hong L, Ahuja N. DNA methylation biomarkers of stool and blood for early detection of colon cancer. Genet. Test. Mol. Biomarkers. 2013;17(5):401–406. - PubMed
-
- Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N. Engl. J. Med. 2014;370(14):1287–1297. - PubMed
-
- Fleischhacker M, Dietrich D, Liebenberg V, Field JK, Schmidt B. The role of DNA methylation as biomarkers in the clinical management of lung cancer. Expert Rev. Respir. Med. 2013;7(4):363–383. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous